ICON Public (NASDAQ:ICLR) Issues FY 2025 Earnings Guidance

ICON Public (NASDAQ:ICLR) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 13.000-15.000 for the period, compared to the consensus estimate of 14.930. The company issued revenue guidance of $8.1 billion-$8.7 billion, compared to the consensus revenue estimate of $8.5 billion. ICON Public also updated its FY 2024 guidance to 13.900-14.100 EPS.

ICON Public Stock Down 0.4 %

ICLR stock opened at $199.47 on Thursday. The stock has a market capitalization of $16.46 billion, a price-to-earnings ratio of 22.24, a price-to-earnings-growth ratio of 1.59 and a beta of 1.20. The company has a 50-day moving average of $210.79 and a two-hundred day moving average of $270.01. ICON Public has a 52-week low of $183.38 and a 52-week high of $347.72. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.72 by ($0.37). The company had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The company’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.10 EPS. As a group, equities research analysts anticipate that ICON Public will post 13.41 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Evercore ISI reduced their target price on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Royal Bank of Canada reiterated an “outperform” rating and issued a $263.00 price objective on shares of ICON Public in a research report on Wednesday. Leerink Partners restated an “outperform” rating and set a $255.00 price objective (down from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Redburn Atlantic began coverage on ICON Public in a research note on Monday, October 14th. They issued a “neutral” rating and a $311.00 target price for the company. Finally, Leerink Partnrs raised shares of ICON Public to a “strong-buy” rating in a report on Wednesday, September 18th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, ICON Public currently has an average rating of “Moderate Buy” and an average price target of $287.00.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.